Skip to content
Terminus Peptides
  • Research use only — not for human or veterinary use
  • 55 compound profiles, every source cited
  • 62 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Biological material

Thymalin

Also known as Thymus peptide preparation

Early human — evidence level 3 of 4: Early human evidenceExperimental — UK regulatory status: Experimental — not authorised for human use in the UK

Overview

A peptide preparation derived from thymus tissue, developed in the Soviet Union and studied almost entirely by one research programme.

Category
Biological material
Highest evidence level identified
Early human evidence
Last scientifically reviewed
20 August 2026
Last regulatory review
20 August 2026

Mechanism under investigation

Thymalin is a peptide preparation derived from thymus tissue, developed in the Soviet Union and Russia, and described by its originators as a thymic immunomodulator. Proposed mechanisms include effects on T-lymphocyte differentiation and on haematopoietic stem cell differentiation. These are proposed rather than independently established, and the preparation is a tissue-derived extract rather than a single characterised molecular entity.

Research areas

  • Immune modulation
  • Ageing research

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

Present but almost entirely from the originating research programme.

Animal evidence

Studies in living non-human animals.

Present, including rat models of tissue regeneration, some from Ukrainian groups.

Human observational evidence

Studies observing people without assigning an intervention.

Present but methodologically weak. The most-cited claim is a report of 266 elderly people followed over six to eight years, claiming reduced respiratory illness and mortality reductions of between 1.6 and 4.1-fold. Effect sizes of that magnitude are themselves a reason for caution, being implausible relative to any established geroprotective intervention.

Clinical-trial evidence

Studies assigning an intervention to human participants.

Effectively absent by contemporary standards. A targeted search combining the compound with randomisation and placebo terms returned no randomised placebo-controlled trials. Reports relating to COVID-19 are non-randomised comparisons of standard care with and without the preparation.

Study limitations

  • Single-programme provenance. The literature is dominated by one St Petersburg group and its affiliates — the same structural problem as epitalon.
  • No randomised, placebo-controlled, double-blind trial was located anywhere in the indexed literature.
  • Key long-term claims appear in journals with limited international visibility, and several foundational reports are not fully indexed.
  • It is a tissue-derived extract, so composition may vary between preparations, which undermines reproducibility and makes independent replication harder.
  • Reported registration as a medicine in Russia could not be verified against an official regulatory register and should not be treated as established.

UK regulatory context

Experimental — not authorised for human use in the UK

A compound appearing in research literature that holds no UK authorisation for human use in any indication.

Source: Supply unlicensed medicinal products (specials) (opens gov.uk in a new tab) (Medicines and Healthcare products Regulatory Agency)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

Published reports from the originating programme do not describe significant adverse effects, but this reassurance is weak: the studies were not designed or powered for safety detection, were not independently monitored, and adverse event reporting does not meet modern standards. As a tissue-derived preparation of variable composition with no independent toxicology in the public domain, the safety profile should be regarded as genuinely uncharacterised rather than favourable.

References